Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04806035 |
| Title | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Fayetteville | Arkansas | 72703 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Hackensack | New Jersey | 07601 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Chattanooga | Tennessee | 37404 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Nashville | Tennessee | 37203 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Houston | Texas | 77030 | United States | Details |